<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119988</url>
  </required_header>
  <id_info>
    <org_study_id>TIPS-Variceal embolization</org_study_id>
    <nct_id>NCT02119988</nct_id>
  </id_info>
  <brief_title>TIPS Combined With Variceal Embolization for the Prevention of Variceal Rebleeding in Patients With Cirrhosis</brief_title>
  <official_title>Transjugular Intrahepatic Portosystemic Shunt (TIPS) Using Covered Stents Combined With Variceal Embolization in the Prevention of Variceal Rebleeding for Patients With Cirrhosis : a Prospective, Open-labeled, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Air Force Military Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Air Force Military Medical University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether TIPS combined with variceal embolization&#xD;
      are effective in the prevention of variceal rebleeding in patients with liver cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variceal bleeding is one of the leading causes of death in patients with cirrhosis. Patients&#xD;
      with cirrhosis surviving a variceal bleeding are at high risk of rebleeding (over 60% at 1&#xD;
      year), and mortality from each rebleeding episode is about 20%.&#xD;
&#xD;
      Placement of TIPS is a well-established technique that is highly effective in preventing&#xD;
      recurrent variceal bleeding, especially if the TIPS is created with an expanded&#xD;
      polytetrafluoroethylene (ePTFE)-covered stent, which has a significantly lower risk of shunt&#xD;
      dysfunction than does TIPS created with bare stents. But the risk of hepatic encephalopathy&#xD;
      greatly increases and the risk of recurrent variceal bleeding after TIPS placement remains an&#xD;
      issue. Besides an insufficient decrease in portosystemic pressure gradient after TIPS&#xD;
      creation alone, fragile variceal vessels also are considered a risk factor for recurrent&#xD;
      bleeding.&#xD;
&#xD;
      Accordingly, TIPS combined with variceal embolization has been advocated to achieve the best&#xD;
      result possible in preventing recurrent variceal bleeding. However, in recent American&#xD;
      Association of the Study of Liver Disease (AASLD) practice guidelines and Baveno V consensus,&#xD;
      no treatment strategies were clearly recommended maybe because the exact efficacy of this&#xD;
      strategy remains unclear and high-quality randomized controlled trials still lacks.&#xD;
&#xD;
      So the investigators hypothesized that embolization of these collateral vessels may increase&#xD;
      the blood flow within the shunt and into the liver, which can theoretically decrease the&#xD;
      incidence of shunt dysfunction and encephalopathy, even can prolong the patients' survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause rebleeding</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>variceal rebleeding</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>shunt dysfunction</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic encephalopathy</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function changs</measure>
    <time_frame>one year</time_frame>
    <description>Child-Pugh score changing by 2 or more points or MELD score by 4 or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>TIPS combined with embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The covered stents were used for TIPS&#xD;
The gastroesophageal collaterals will be embolized during the procedure of TIPS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIPS alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The covered stents were used for TIPS&#xD;
No embolization of any collateral will be performed during TIPS</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TIPS</intervention_name>
    <description>TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. TIPS revision was planned if any evidence of shunt dysfunction was seen.</description>
    <arm_group_label>TIPS alone</arm_group_label>
    <arm_group_label>TIPS combined with embolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embolization</intervention_name>
    <description>Embolization of gastroesophageal collaterals was conducted via the same jugular vein before TIPS implantation. The major procedures included (a)angiography of gastroesophageal collaterals after successful intrahepatic puncture of a branch of the portal vein and (b)embolization of SPSS with coils of varying diameters, which resulted in the gastroesophageal collaterals disappearing at postembolization angiography.</description>
    <arm_group_label>TIPS combined with embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Dignosis of cirrhosis (clinical or by liver biopsy)&#xD;
&#xD;
          -  Admission due to variceal bleeding occurred 5 to 42 days prior and standard treatment&#xD;
             for secondary prophylaxis failed&#xD;
&#xD;
          -  Age 18 to 75 years&#xD;
&#xD;
          -  Child-Pugh score ≤13&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic carcinoma and/or other malignancy diseases&#xD;
&#xD;
          -  Portal vein thrombosis (≥50% of the lumen)&#xD;
&#xD;
          -  Budd-Chiari syndrome&#xD;
&#xD;
          -  Spontaneous portosystemic shunts&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Spontaneous bacterial peritonitis&#xD;
&#xD;
          -  Uncontrollable hypertension&#xD;
&#xD;
          -  Serious cardiac or pulmonary dysfunction&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  With TIPS contraindications&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  History of organ transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guohong Han, PhD &amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital of Digestive Diseases, Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guohong Han, PhD,MD</last_name>
    <phone>86-29-84771528</phone>
    <email>hangh@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Chen, MD</last_name>
    <phone>86-29-84771528</phone>
    <email>qychenhui@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital of digestive disease, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han</last_name>
      <email>hangh@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Guohong Han, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guohong Han, MD,Ph.D</last_name>
      <phone>86-29-84771528</phone>
      <email>hangh@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hui Chen, MD</last_name>
      <phone>86-29-84771528</phone>
      <email>qychenhui@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guohong Han, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2014</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Air Force Military Medical University, China</investigator_affiliation>
    <investigator_full_name>Guohong Han</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>TIPS</keyword>
  <keyword>Embolization</keyword>
  <keyword>Variceal rebleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

